Objective
Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!
Antibiotic resistance is a global public health concern recently elevated to the top three threats identified by the WHO, and subject of numerous national and international government activities. Although focused strategies have beneficially influenced infection rates due to methicillin resistant Staphylococcus aureus (MRSA), infections due to MDR-GNB are rapidly increasing. In a very recent report the Centers for Disease Control and Prevention concluded that Carbapenem-Resistant Enterobacteriaceae (CRE) represent an immediate public health threat that requires urgent and aggressive action (CDC: Antibiotic Resistance Threats in the United States 2013).
The epidemiology of MDR-GNB, and especially of CRE, is characterized by large heterogeneity in genotypes (with >20 reported resistance genes, such as NDM, KPC, VIM, OXA-48) and even larger heterogeneity of phenotypes, seriously hampering rapid detection of resistant types when using routine susceptibility testing. Treatment of infections caused by CRE relies on combinations of “older” antibiotics, lacking a strong evidence base of effectiveness and safety. New treatments for these infections are, therefore, urgently needed.
The COMBACTE-CARE consortium is building on the recently funded Topic 1a/b/c consortium: COMBACTE, and contains three networks: CLIN-Net, LAB-Net and STAT-Net. To fulfil the specific objectives of Topic 5 the consortium has focussed on capacity building in clinical sites in some of the new member states in south-eastern Europe, where infection rates with MDR-GNB are expected to be high. Together with high-quality study sites in countries with endemic levels of MDR-GNB (such as Israel and Greece) CLIN-Net and LAB-Net will maximize capacity to provide a highly efficient resource for the conduct of the proposed studies on ATM-AVI. Furthermore, the consortium brings in four of the most prominent MDR-GNB diagnostic research groups in Europe, able to address the diagnostic challenges for the epidemiological and clinical studies, and a highly successful – and already operational – cohort for biomarker identification in critically ill patients. Furthermore, the participation of the PENTA network offers the unique opportunity to efficiently include neonates and children in the observational studies.
The COMBACTE-CARE consortium brings together 20 academic partners (10 also partner in COMBACTE) and two CROs that build upon prior EU Commission investments which present unique expertise and capabilities to the overall project partnership.
For all these reasons, APC2 (aligned with the COMBACTE infrastructure) will (1) increase the efficiency of antibiotic R&D through analysing observational clinical and microbiological data sets and making recommendations for the development of novel antibiotic agents for MDR GNB; will (2) provide new knowledge on the clinical management and outcomes of patients (neonates/children and adults) with serious hospitalised infections and will validate this knowledge for clinical outcomes for patients in areas of emerging and endemic antibiotic resistance; will (3) support the sustainability of ND4BB supported investigator and laboratory networks (COMBACTE); will (4) conduct prospective clinical trials with novel trial designs to deliver safety, pharmacology, and proof of efficacy data for novel agents directed towards treatment of infections due to MDR pathogens, prevention or sequelae of infections due to priority pathogens; will (5) validate novel bacterial identification and follow-up diagnostics or clinical endpoints with the aim of reducing the size and cost of clinical trials; and will (6) provide new knowledge on biomarkers predicting poor outcome in patients with serious healthcare-associated infections.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences microbiology bacteriology
- medical and health sciences health sciences public health epidemiology epidemics prevention
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance multidrug resistance
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
IMI-JU-09-2013
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)
Coordinator
CT13 9NJ Sandwich
United Kingdom
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
Participants (22)
3584 CX Utrecht
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
1211 Geneve
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
87000 Limoges
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
41071 SEVILLA
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
50937 Koeln
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
64239 Tel Aviv
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
10 561 ATHINA
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
75654 PARIS
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
SW17 0RE London
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
10000 PRISTINA
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
Participation ended
9713 GZ Groningen
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
31096 Haifa
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
CF10 3AT CARDIFF
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
28046 MADRID
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
08036 Barcelona
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
1105AZ Amsterdam
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
2000 Antwerpen
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
89081 Ulm
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
WC1A 1DG LONDON
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
4058 BASEL
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
Participation ended
151 85 Sodertaelje
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
79106 Freiburg
See on map
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.